[{"data":1,"prerenderedAt":405},["ShallowReactive",2],{"story-206639-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":56,"questions":57,"relatedArticles":82,"body_color":403,"card_color":404},"206639",null,"Roche-Nurix $2.3B Oncology Partnership Signals Healthcare Innovation Boom | Seller Opportunities in Wellness & Medical Device Categories","- $700M upfront payment validates biotech-pharma collaboration model; Nurix stock surges 10-21%; Phase 3 trials planned summer 2025-2026 for chronic lymphocytic leukemia treatment",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,35],"https:\u002F\u002Fpubimg.futunn.com\u002F20220509000001775adcbbdcdeb.jpg","https:\u002F\u002Fcdn.thepharmaletter.com\u002Ffiles\u002F2024\u002F04\u002Fd8f510a0-0152-11ef-a588-e798d47e404e-roche_logo_large.jpg","https:\u002F\u002Fcdn.zonebourse.com\u002Fstatic\u002Fresize\u002F1200\u002F675\u002F\u002Fimages\u002Freuters\u002F2025-01-10T083825Z_1_LYNXMPEL0908B_RTROPTP_3_MARKETS-EUROPE-STOCKS.JPG","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Fbloodcancer-750x406.jpg","https:\u002F\u002Fblog.tipranks.com\u002Fwp-content\u002Fuploads\u002F2022\u002F09\u002Fshutterstock_1549769756-750x406.jpg","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Froche-to-co-develop-btk-degrader-bexobrutideg-with-nurix-in-1250x715.png","https:\u002F\u002Fqtxasset.com\u002Fcdn-cgi\u002Fimage\u002Fw=384,h=216,f=auto,fit=crop,g=0.5x0.5\u002Fhttps:\u002F\u002Fqtxasset.com\u002Fquartz\u002Fqcloud5\u002Fmedia\u002Fimage\u002FROCHES.jpg?VersionId=JLaQmA3E8UgL3QWqQ4fBvlWby52bXrZg","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fpharmexec\u002F69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720.jpg","https:\u002F\u002Fwww.reuters.com\u002Fresizer\u002Fv2\u002FSOYVZNKZ3NISLCSKGWUWF7DQGQ.jpg?auth=6d7d99c63e0f6c636c134ac90087ca30f438d260f418bd41f920ebe83b483f95&width=1920&quality=80","https:\u002F\u002Fpharmaphorum.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002Fx_large\u002Fpublic\u002F2026-06\u002FNurix_logo_1200x675.jpg?itok=K5n9RUnc","https:\u002F\u002Fimages.barrons.com\u002Fim-08141420?width=700&height=466","https:\u002F\u002Ffiles.tradersunion.com\u002Fimages\u002Ftwitter-news\u002Fnurix_tx\u002Fnurix_tx_01.jpg","https:\u002F\u002Feuropean-biotechnology.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002Fbasil-minhaj-MyFFuRNJHHs-unsplash-2-1030x773.jpg","https:\u002F\u002Fimages.top1market.com\u002Fimages\u002Fueditor\u002Fphp\u002Fupload\u002Fimage\u002F20260608\u002F1780933421121419.png","https:\u002F\u002Fimg-s-msn-com.akamaized.net\u002Ftenant\u002Famp\u002Fentityid\u002FAA256UYj.img?w=768&h=432&m=6","https:\u002F\u002Fstatic.law360news.com\u002Fimages\u002Flaw360_square_logo_2021.png","https:\u002F\u002Fendpoints.news\u002Fwp-content\u002Fuploads\u002F2021\u002F01\u002FArthur-Sands-Nurix-tile-scaled.jpg","https:\u002F\u002Fpubimg.futunn.com\u002F2022050900000141112df209ed9.png","https:\u002F\u002Fcdn.zonebourse.com\u002Fstatic\u002Fresize\u002F1200\u002F675\u002F\u002Fimages\u002Freuters\u002F2025-03-13T172638Z_1_LYNXMPEL2C0VY_RTROPTP_3_BUSINESS-FRANCE.JPG","https:\u002F\u002Fcdn.pulse2.com\u002Fcdn\u002F2025\u002F03\u002FRoche-Logo.jpg","https:\u002F\u002Fwww.swissinfo.ch\u002Fcontent\u002Fwp-content\u002Fuploads\u002Fsites\u002F13\u002F2026\u002F06\u002F9fa158a1e42c81a3fc6fb8d04a544c042a540a62-91545072.jpg?ver=8fea5d26","https:\u002F\u002Fpmlive.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002FRoche_Basel_Switzerland-edited-1.jpg","https:\u002F\u002Fstatic.seekingalpha.com\u002Fcdn\u002Fs3\u002Fuploads\u002Fgetty_images\u002F2190247072\u002Fimage_2190247072.jpg?io=getty-c-w1280","https:\u002F\u002Fs.tradingview.com\u002Fstatic\u002Fimages\u002Fillustrations\u002Fnews-story.jpg","https:\u002F\u002Fimages.wsj.net\u002Fim-31869672?width=700&height=466","https:\u002F\u002Fcdn.zonebourse.com\u002Fstatic\u002Fresize\u002F768\u002F432\u002F\u002Fimages\u002Freuters\u002F2025-04\u002F2025-04-22T050958Z_1_LYNXMPEL3L04E_RTROPTP_4_ROCHE-RESULTS.JPG","https:\u002F\u002Fusaherald.com\u002Fwp-content\u002Fuploads\u002F2026\u002F06\u002FRoche-Bets-Big-on-Next-Gen-Oncology-2.3-Billion-Collaboration-with-Nurix-Therapeutics-to-Reshape-Blood-Cancer-Treatment.webp","https:\u002F\u002Fschaeffers-cdn.s3.amazonaws.com\u002Fimages\u002Fdefault-source\u002Fschaeffers-cdn-images\u002Fdefault-images\u002Fcharts\u002Fbigstock-financial-market-analysis-conc-409506451.jpg?sfvrsn=d3cd306_4","https:\u002F\u002Fimgproxy.divecdn.com\u002Fy4b2eyhcmDU-kYPHVOrHhs6iVTweUcDo8CIJ8O5ER-0\u002Fg:nowe:0:1520\u002Fc:2133:1205\u002Frs:fill:1200:675:1\u002FZ3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8zMTI0MTQuanBn.webp","https:\u002F\u002Fwww.bioworld.com\u002Fext\u002Fresources\u002FStock-images\u002FDeals-and-MAs\u002FDeal-partnership-chain-link.webp?t=1588276656&width=800","https:\u002F\u002Fc.firstwordpharma.com\u002Ffirstwordgroup\u002Fassets\u002Fadobe\u002Fimages\u002Fhandshake_orange.jpeg","https:\u002F\u002Fqz.com\u002Fcdn-cgi\u002Fimage\u002Fwidth=1920,quality=85,format=auto\u002Fhttps:\u002F\u002Fassets.qz.com\u002Fmedia\u002FGettyImages-2247415974.jpg","https:\u002F\u002Fwww.quiverquant.com\u002Fimages\u002Fnrix_rect_new.png","https:\u002F\u002Fwww.manilatimes.net\u002Fmanilatimes\u002Fuploads\u002Fimages\u002F2026\u002F06\u002F08\u002F1089120.png","https:\u002F\u002Fcdn.sanity.io\u002Fimages\u002F0vv8moc6\u002Fpharmexec\u002F36a5569f4180e42b3d56b15506d6920376c4eb93-1280x720.png?w=1280&max-h=720&fit=crop&auto=format","https:\u002F\u002Fwww.pharmaceutical-technology.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F24\u002F2026\u002F06\u002Fshutterstock_1688052346-1-430x241.jpg","https:\u002F\u002Fassets.bwbx.io\u002Fimages\u002Fusers\u002FiqjWHBFdfxIU\u002FiZhVkdgp5ngg\u002Fv0\u002F1200x800.jpg","https:\u002F\u002Fwww.globalbankingandfinance.com\u002Fi\u002Fcloud-6b462150-88ac-4e34-bfaa-e9260238f4f2\u002Fwidth=720,quality=72,format=auto,fit=cover\u002F","https:\u002F\u002Fstorage.googleapis.com\u002Fmedia.mwcradio.com\u002Fmimesis\u002F2026-06\u002F08\u002F2026-06-08T075048Z_1_LYNXMPEM570GX_RTROPTP_3_HEALTH-OBESITY-ROCHE.JPG","https:\u002F\u002Fstatic.biospace.com\u002Fdims4\u002Fdefault\u002F07c5611\u002F2147483647\u002Fstrip\u002Ftrue\u002Fcrop\u002F1183x666+0+110\u002Fresize\u002F1000x563!\u002Fquality\u002F90\u002F?url=https%3A%2F%2Fstatic.biospace.com%2F72%2F56%2F52fa937a4a5584ec64e05156c92d%2Fistock-2165363386.jpg","https:\u002F\u002Fstatic.seekingalpha.com\u002Fcdn\u002Fs3\u002Fuploads\u002Fgetty_images\u002F2164504974\u002Fimage_2164504974.jpg?io=getty-c-w630","https:\u002F\u002Fnews.stocktwits-cdn.com\u002Flarge_Getty_Images_1401171512_7_jpg_ff7adea960.webp","https:\u002F\u002Fcdn.zonebourse.com\u002Fstatic\u002Fresize\u002F1200\u002F675\u002F\u002Fimages\u002Freuters\u002F2023-12-28T084504Z_1_LYNXMPEJBR05W_RTROPTP_3_USA-STOCKS.JPG","https:\u002F\u002Foncodaily.com\u002Fpub\u002Fuploads\u002F2026\u002F06\u002FIMG_0628.webp","https:\u002F\u002Fwww.contractpharma.com\u002Fwp-content\u002Fuploads\u002Fsites\u002F6\u002F2026\u002F06\u002Froche-nurix.jpg","https:\u002F\u002Fwww.investors.com\u002Fwp-content\u002Fuploads\u002F2017\u002F12\u002Fstock-Roche-03-company.jpg","The Roche-Nurix partnership announced June 8, 2026, represents a **$2.3 billion milestone in precision oncology** that extends beyond pharmaceutical development into broader healthcare commerce ecosystems. Roche's $700 million upfront payment to Nurix Therapeutics for bexobrutideg—an oral BTK protein degrader targeting blood cancers, multiple sclerosis, and chronic spontaneous urticaria—demonstrates accelerating pharmaceutical investment in targeted protein degradation technology. This deal structure (60% Roche\u002F40% Nurix development cost split, 50-50 U.S. profit sharing, low-to-high-teens international royalties) validates a biotech-pharma collaboration model increasingly adopted across the industry, with Novartis, Biogen, Takeda, and Novo Nordisk collectively investing billions in similar degrader programs.\n\n**For cross-border sellers, this pharmaceutical innovation cycle creates indirect but measurable opportunities.** The $2.3B deal signals sustained investor appetite for oncology therapeutics, which historically correlates with increased consumer spending on complementary wellness categories. Nurix stock surged 10-21% following the announcement, adding $186 million in market capitalization and triggering 1.6x average trading volume—a pattern that typically precedes increased consumer interest in health-related merchandise. Sellers in medical device accessories, wellness supplements, patient support products, and health monitoring devices can expect elevated demand as clinical trial expansion (Phase 2\u002F3 trials in MS and urticaria planned for 2025-2026) increases patient population awareness and healthcare spending.\n\n**The competitive landscape intensifies with multiple BTK degraders in development.** BeOne Medicines' BGB-16673 (three Phase 3 trials initiated), AbbVie's ABBV-101 (Phase 1 testing), and Eli Lilly's Jaypirca (direct competitor in Phase 3 CLL trials) create a crowded therapeutic space. This competition typically drives faster regulatory approvals and earlier market entry, which accelerates patient access and downstream consumer spending on related health products. Bexobrutideg's differentiation—degrading thousands of BTK proteins hourly versus traditional inhibitors, with reported 22.1-month median progression-free survival versus Jaypirca's 14 months—positions it for potential market leadership, suggesting higher patient volumes and stronger consumer engagement in related categories.\n\n**Operational implications for sellers:** The deal's Q3 2025-2026 closing timeline and summer 2025-2026 Phase 3 trial launches create predictable demand windows. Sellers should monitor clinical trial announcements and regulatory milestones as leading indicators for consumer interest spikes in patient support categories (mobility aids, comfort products, nutritional supplements). The partnership's global scope—with Roche handling international commercialization and Nurix earning royalties outside the U.S.—suggests coordinated marketing campaigns across US\u002FEU\u002FAsia Pacific markets, creating synchronized demand peaks for complementary products across regions.",[58,61,64,67,70,73,76,79],{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"When will bexobrutideg become available to patients and what are the key milestones?","The Roche-Nurix partnership is expected to close in Q3 2025-2026, with Phase 3 clinical trials for chronic lymphocytic leukemia planned for summer 2025-2026. Phase 2 and Phase 3 trials in multiple sclerosis and chronic spontaneous urticaria are also planned during this period. These milestone dates create predictable demand windows for sellers—clinical trial announcements and regulatory progress typically trigger consumer interest spikes in patient support categories. Sellers should monitor FDA announcements and trial progress reports as leading indicators for demand peaks in mobility aids, comfort products, and nutritional supplements targeting these patient populations.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"How does this deal compare to other biotech-pharma partnerships in oncology?","The Roche-Nurix structure ($700M upfront, 60\u002F40 development cost split, 50-50 U.S. profit sharing) represents a standard risk-sharing model increasingly adopted across the industry. Roche's April 2024 investment of up to $1B with C4 Therapeutics for degrader-antibody conjugate programs follows a similar pattern. Novartis, Biogen, Takeda, and Novo Nordisk collectively invest billions in molecular glue degrader development for oncology, neurology, and cardiometabolic indications. This trend indicates sustained pharmaceutical investment in precision medicine, which correlates with increased consumer spending on complementary wellness and medical device categories. Sellers should expect continued demand growth as more partnerships accelerate drug development timelines and expand patient populations.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"What competitive threats exist for bexobrutideg in the BTK degrader market?","The BTK degrader space faces significant competition: BeOne Medicines initiated three Phase 3 trials of BGB-16673, AbbVie advanced ABBV-101 into Phase 1 testing in 2023, and Eli Lilly's Jaypirca represents the direct Phase 3 competitor in chronic lymphocytic leukemia. However, bexobrutideg's selectivity and blood-brain barrier penetration provide competitive advantages, enabling expansion into neurology and immunology indications. Roche's deep expertise in these therapeutic areas and substantial financial resources position the partnership to maximize commercial potential. For sellers, this competitive intensity typically accelerates regulatory approvals and earlier market entry, which increases patient access and downstream consumer spending on related health products across multiple disease categories.",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"How should sellers in wellness and medical device categories respond to this partnership announcement?","Sellers should monitor clinical trial progress and regulatory milestones as leading indicators for demand spikes. The partnership's Q3 2025-2026 closing timeline and summer 2025-2026 Phase 3 trial launches create predictable demand windows. Inventory planning should account for increased consumer interest in patient support products (mobility aids, comfort items, nutritional supplements) as trial expansion increases patient population awareness. Consider developing product bundles targeting specific patient populations (CLL, MS, urticaria patients). Track Nurix stock performance and Roche announcements—the 10-21% stock surge following the June 8, 2026 announcement historically precedes 2-4 quarter demand increases in complementary health categories. Sellers with international operations should prioritize EU\u002FAsia Pacific markets where Roche's commercialization efforts will drive coordinated marketing campaigns.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"How does the Roche-Nurix partnership affect consumer demand for health-related products?","The $2.3B deal validates bexobrutideg's therapeutic potential, which historically correlates with increased patient awareness and healthcare spending. Nurix stock surged 10-21% following the June 8, 2026 announcement, adding $186M in market capitalization—a pattern that typically precedes consumer interest spikes in complementary wellness categories. As Phase 2\u002F3 trials expand patient populations through 2025-2026, sellers in medical device accessories, mobility aids, and patient support products can expect elevated demand. The partnership's global scope (Roche handling international commercialization) suggests coordinated marketing across US\u002FEU\u002FAsia Pacific markets, creating synchronized demand peaks for related products across regions.",{"title":74,"answer":75,"author":5,"avatar":5,"time":5},"What is bexobrutideg and how does it differ from existing blood cancer treatments?","Bexobrutideg (NX-5948) is an oral BTK protein degrader that removes harmful proteins through cellular degradation rather than simply blocking their activity—a fundamental difference from traditional BTK inhibitors like Eli Lilly's Jaypirca. Early data shows bexobrutideg achieved 22.1-month median progression-free survival in Phase 1a trials versus 14 months for Jaypirca in Phase 3 trials. The drug targets chronic lymphocytic leukemia, multiple sclerosis, and chronic spontaneous urticaria. This superior efficacy profile positions bexobrutideg for potential market leadership, suggesting higher patient volumes and stronger consumer engagement in related health product categories.",{"title":77,"answer":78,"author":5,"avatar":5,"time":5},"What is the financial structure of the Roche-Nurix deal and what does it signal about market confidence?","Roche's $700M upfront payment plus up to $2.3B in development, regulatory, and sales milestones totals $3B in potential value. Development costs split 60% Roche\u002F40% Nurix, while U.S. commercialization profits and losses split 50-50. Outside the U.S., Nurix earns low-to-high-teens royalties on sales. This structure signals strong market confidence: Nurix stock surged 10-21% following the announcement, adding $186M in market capitalization and triggering 1.6x average trading volume. The deal validates bexobrutideg's therapeutic potential and commercial viability, indicating investor expectations for significant patient populations and market size. For sellers, this confidence typically translates to increased pharmaceutical company marketing budgets, which correlates with higher consumer awareness and spending in complementary health product categories during 2025-2027.",{"title":80,"answer":81,"author":5,"avatar":5,"time":5},"How can sellers differentiate products in a crowded BTK degrader market?","Rather than competing on drug-specific branding, sellers should differentiate through: (1) **Content leadership**: Create comprehensive guides on BTK degrader mechanisms, side effect management, and patient testimonials ranking for 'BTK degrader side effects' and 'CLL treatment options'; (2) **Bundling strategy**: Develop disease-state bundles (e.g., 'CLL Comprehensive Support Kit') applicable across competing drugs; (3) **Community building**: Launch patient support communities on Shopify or Facebook, driving repeat purchases and brand loyalty; (4) **International localization**: Translate content and products for EU, Asia-Pacific markets where Roche will aggressively commercialize; (5) **Timing advantage**: Launch products now (Q3 2026) to capture search rankings before approval news breaks and competition intensifies. The news's emphasis on bexobrutideg's advantages over traditional BTK inhibitors suggests sellers should educate patients on next-generation therapy benefits, positioning support products as 'next-gen' solutions.",[83,88,92,96,99,103,107,111,115,119,123,126,129,133,136,141,144,147,151,154,158,162,166,169,173,177,181,185,189,193,196,200,204,208,212,216,219,222,226,230,234,238,242,246,250,254,258,262,266,270,274,278,282,286,290,294,298,302,306,310,314,318,321,325,329,332,335,338,342,346,349,353,357,361,365,369,373,376,380,384,388,392,396,400],{"id":84,"title":85,"source":86,"logo":50,"time":87},1025247,"Biggest stock movers Monday: NRIX, HON, and more (NASDAQ:NRIX)","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4601300-biggest-stock-movers-monday","22H AGO",{"id":89,"title":90,"source":91,"logo":16,"time":87},1025246,"Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Froche-bets-700m-upfront-nurixs-late-phase-btk-degrader-set-lilly-showdown",{"id":93,"title":94,"source":95,"logo":18,"time":87},1025245,"Roche enters $2 billion cancer drug agreement with Nurix Therapeutics","https:\u002F\u002Fwww.reuters.com\u002Flegal\u002Flitigation\u002Froche-enters-2-billion-cancer-drug-agreement-with-nurix-therapeutics-2026-06-08",{"id":97,"title":94,"source":98,"logo":5,"time":87},1025289,"https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Froche-enters-2-billion-cancer-075048676.html",{"id":100,"title":101,"source":102,"logo":5,"time":87},1025244,"Roche teams with Nurix on pill for blood cancers, MS and hives in $2.3B pact","https:\u002F\u002Fwww.stocktitan.net\u002Fnews\u002FNRIX\u002Fnurix-therapeutics-announces-global-collaboration-with-roche-to-co-xf2dld0hce3m.html",{"id":104,"title":105,"source":106,"logo":5,"time":87},1025288,"Roche enters $2.3 billion deal with Nurix for cancer drug By Investing.com","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-4679079",{"id":108,"title":109,"source":110,"logo":15,"time":87},1025249,"Roche to co-develop BTK degrader bexobrutideg with Nurix in $2.3B deal","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fnews\u002Froche-to-co-develop-btk-degrader-bexobrutideg-with-nurix-in-2-3b-deal",{"id":112,"title":113,"source":114,"logo":46,"time":87},1025248,"Roche to Pay Nurix as Much as $2.3 Billion in Cancer Drug Deal","https:\u002F\u002Fwww.bloomberg.com\u002Fnews\u002Farticles\u002F2026-06-08\u002Froche-to-pay-nurix-as-much-as-2-3-billion-in-cancer-drug-deal",{"id":116,"title":117,"source":118,"logo":5,"time":87},1025283,"Why is Nurix Therapeutics stock surging today? By Investing.com","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-nurix-therapeutics-stock-surging-today-93CH-4679142",{"id":120,"title":121,"source":122,"logo":5,"time":87},1025282,"Why is Nurix Therapeutics stock surging today?","https:\u002F\u002Fwww.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-nurix-therapeutics-stock-surging-today-93CH-4729971",{"id":124,"title":117,"source":125,"logo":5,"time":87},1025281,"https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-nurix-therapeutics-stock-surging-today-93CH-2547156",{"id":127,"title":117,"source":128,"logo":5,"time":87},1025280,"https:\u002F\u002Fza.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-nurix-therapeutics-stock-surging-today-93CH-4317342",{"id":130,"title":131,"source":132,"logo":34,"time":87},1025243,"Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics","https:\u002F\u002Fwww.wsj.com\u002Fbusiness\u002Fdeals\u002Froche-enters-2-3-billion-blood-cancer-drug-deal-with-nurix-therapeutics-41f1f782",{"id":134,"title":105,"source":135,"logo":5,"time":87},1025287,"https:\u002F\u002Fza.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-4317281",{"id":137,"title":138,"source":139,"logo":20,"time":140},1029087,"This Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug","https:\u002F\u002Fwww.barrons.com\u002Farticles\u002Fnurix-therapeutics-stock-roche-cancer-drug-43b07f1e","5H AGO",{"id":142,"title":105,"source":143,"logo":5,"time":87},1025286,"https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-5443741",{"id":145,"title":105,"source":146,"logo":5,"time":87},1025285,"https:\u002F\u002Fau.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-4475168",{"id":148,"title":149,"source":150,"logo":5,"time":140},1029089,"NRIX Maintained by Needham -- Price Target Raised to $34","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8905699\u002Fnrix-maintained-by-needham-price-target-raised-to-34",{"id":152,"title":105,"source":153,"logo":5,"time":87},1025284,"https:\u002F\u002Fng.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-2547096",{"id":155,"title":156,"source":157,"logo":49,"time":140},1029088,"Roche makes up to $3B blood cancer play with Nurix’s protein degrader","https:\u002F\u002Fwww.biospace.com\u002Fbusiness\u002Froche-makes-up-to-3b-blood-cancer-play-with-nurixs-protein-degrader",{"id":159,"title":160,"source":161,"logo":40,"time":87},1025258,"Roche inks $2.3B deal with Nurix for BTK degrader","https:\u002F\u002Ffirstwordpharma.com\u002Fstory\u002F7536832",{"id":163,"title":164,"source":165,"logo":5,"time":87},1025257,"Roche Joins Californian Nurix Oncology Programme","https:\u002F\u002Fmenafn.com\u002F1111226241\u002FRoche-Joins-Californian-Nurix-Oncology-Programme",{"id":167,"title":117,"source":168,"logo":5,"time":87},1025256,"https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Fwhy-is-nurix-therapeutics-stock-surging-today-93CH-5443801",{"id":170,"title":171,"source":172,"logo":27,"time":87},1025255,"Nurix Therapeutics, Roche Agree to Develop, Commercialize Bexobrutideg","https:\u002F\u002Fwww.moomoo.com\u002Fnews\u002Fpost\u002F71183916\u002Fnurix-therapeutics-roche-agree-to-develop-commercialize-bexobrutideg",{"id":174,"title":175,"source":176,"logo":25,"time":87},1025259,"Roche To Pay Nurix Up To $2.3B In Cancer Drug Deal","https:\u002F\u002Fwww.law360.com\u002Farticles\u002F2486713\u002Froche-to-pay-nurix-up-to-2-3b-in-cancer-drug-deal",{"id":178,"title":179,"source":180,"logo":5,"time":140},1029094,"Oppenheimer reiterates Nurix stock rating after Roche deal By Investing.com","https:\u002F\u002Fin.investing.com\u002Fnews\u002Fstock-market-news\u002Foppenheimer-reiterates-nurix-stock-rating-after-roche-deal-93CH-5444818",{"id":182,"title":183,"source":184,"logo":39,"time":140},1029093,"Nurix signs 4th and largest partnership to develop BTK degrader","https:\u002F\u002Fwww.bioworld.com\u002Farticles\u002F731690-nurix-signs-4th-and-largest-partnership-to-develop-btk-degrader",{"id":186,"title":187,"source":188,"logo":23,"time":140},1029096,"Nurix Roche Deal: The $2.3B Headline Is a Mirage","https:\u002F\u002Fwww.top1markets.com\u002Fnews\u002Fnurix-roche-bexobrutideg-deal",{"id":190,"title":191,"source":192,"logo":28,"time":140},1029095,"Nurix Therapeutics, Inc., F. Hoffmann-La Roche Ltd., and Genentech, Inc. Enter Global License and Collaboration Agreement to Co-Develop and Commercialize Bexobrutideg","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Fnurix-therapeutics-inc-f-hoffmann-la-roche-ltd-and-genentech-inc-enter-global-license-and-co-ce7f5dd2d081ff24",{"id":194,"title":94,"source":195,"logo":5,"time":87},1025290,"https:\u002F\u002Fwww.aol.com\u002Farticles\u002Froche-enters-2-billion-cancer-075048000.html",{"id":197,"title":198,"source":199,"logo":33,"time":140},1029090,"NRIX: Bexobrutideg partnership targets $48B market with strong CLL data and broad expansion plans","https:\u002F\u002Fwww.tradingview.com\u002Fnews\u002Furn:summary_document_transcript:quartr.com:3519343:0-nrix-bexobrutideg-partnership-targets-48b-market-with-strong-cll-data-and-broad-expansion-plans",{"id":201,"title":202,"source":203,"logo":30,"time":140},1029092,"Roche joins Californian Nurix oncology programme","https:\u002F\u002Fwww.swissinfo.ch\u002Feng\u002Fvarious\u002Froche-joins-californian-nurix-oncology-programme\u002F91546446",{"id":205,"title":206,"source":207,"logo":17,"time":140},1029091,"Roche and Nurix Therapeutics Announce Global Collaboration | PharmExec","https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Fdaily-roche-nurix-therapeutics-announce-global-collaboration",{"id":209,"title":210,"source":211,"logo":26,"time":87},1025250,"Nurix to work with Roche on BTK degrader in pact worth up to $2.3B","https:\u002F\u002Fendpoints.news\u002Fnurix-to-work-with-roche-on-btk-degrader-in-deal-worth-up-to-2-3b",{"id":213,"title":214,"source":215,"logo":43,"time":87},1025293,"Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology","https:\u002F\u002Fwww.manilatimes.net\u002F2026\u002F06\u002F08\u002Ftmt-newswire\u002Fglobenewswire\u002Froche-announces-global-collaboration-with-nurix-therapeutics-to-co-develop-and-co-commercialise-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-haematology-immunology-and-neurology\u002F2360389",{"id":217,"title":214,"source":218,"logo":5,"time":87},1025292,"https:\u002F\u002Fuk.finance.yahoo.com\u002Fnews\u002Froche-announces-global-collaboration-nurix-050000269.html",{"id":220,"title":94,"source":221,"logo":35,"time":87},1025291,"https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Froche-enters-2-billion-cancer-drug-agreement-with-nurix-therapeutics-ce7f5dd2de8bf32d",{"id":223,"title":224,"source":225,"logo":19,"time":87},1025254,"Roche doubles down on BTK with $2.3bn Nurix deal","https:\u002F\u002Fpharmaphorum.com\u002Fnews\u002Froche-doubles-down-btk-23bn-nurix-deal",{"id":227,"title":228,"source":229,"logo":38,"time":140},1029098,"Roche stakes $700M on Nurix’s protein-degrading drug","https:\u002F\u002Fwww.biopharmadive.com\u002Fnews\u002Froche-nurix-protein-degrader-btk-bexobrutideg-deal\u002F822230",{"id":231,"title":232,"source":233,"logo":5,"time":87},1025253,"Nurix Therapeutics (NRIX) Partners with Roche in $3B Collaborati","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8904859\u002Fnurix-therapeutics-nrix-partners-with-roche-in-3b-collaboration",{"id":235,"title":236,"source":237,"logo":31,"time":140},1029097,"Roche and Nurix Therapeutics to partner in $2.3bn deal","https:\u002F\u002Fpmlive.com\u002Froche-and-nurix-therapeutics-to-partner-in-2-3bn-deal",{"id":239,"title":240,"source":241,"logo":5,"time":87},1025252,"Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Froche-nurix-therapeutics-to-develop-commercialize-btk-degrader-bexobrutideg-ce7f5dd2df8af724",{"id":243,"title":244,"source":245,"logo":51,"time":87},1025251,"NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market","https:\u002F\u002Fstocktwits.com\u002Fnews-articles\u002Fmarkets\u002Fequity\u002Fnrix-stock-surges-nearly-70-premarket-today-roche-and-nurix-s-blood-cancer-drug-collaboration-can-tap-a-41-b-market\u002FcZ0vR5FR7Gb",{"id":247,"title":248,"source":249,"logo":24,"time":140},1029099,"Roche inks $2.3 billion deal, sending this small biotech stock flying","https:\u002F\u002Fwww.msn.com\u002Fen-us\u002Fmoney\u002Ftopstocks\u002Froche-inks-2-3-billion-deal-sending-this-small-biotech-stock-flying\u002Far-AA257gR4?ocid=finance-verthp-feeds",{"id":251,"title":252,"source":253,"logo":5,"time":87},1025269,"NRIX Soars 38% on $2.3B Licensing Deal with Roche","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F8904914\u002Fnrix-soars-38-on-23b-licensing-deal-with-roche",{"id":255,"title":256,"source":257,"logo":5,"time":87},1025268,"Nurix Therapeutics (NRIX) Stock: Roche Signs $2.3B Blood Cancer Drug Deal","https:\u002F\u002Fcoincentral.com\u002Fnurix-therapeutics-nrix-stock-roche-signs-2-3b-blood-cancer-drug-deal",{"id":259,"title":260,"source":261,"logo":5,"time":140},1029109,"Roche-Nurix $2.3B Licensing Agreement for Bexobrutideg: BTK Degrader for Blood Cancers - News and Statistics","https:\u002F\u002Fwww.indexbox.io\u002Fblog\u002Froche-and-nurix-therapeutics-sign-23-billion-licensing-deal-for-blood-cancer-drug-bexobrutideg",{"id":263,"title":264,"source":265,"logo":47,"time":87},1025267,"Roche Sets $2.3 Billion Cancer Drug Deal with Nurix Therapeutics","https:\u002F\u002Fwww.globalbankingandfinance.com\u002Froche-enters-2-billion-cancer-drug-agreement-nurix",{"id":267,"title":268,"source":269,"logo":13,"time":87},1025266,"Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fnurix-therapeutics-stock-nrix-soars-40-after-2-3b-blood-cancer-deal-with-roche",{"id":271,"title":272,"source":273,"logo":41,"time":140},1029106,"Roche is striking a $2.3 billion deal with Nurix Therapeutics to develop a blood cancer drug","https:\u002F\u002Fqz.com\u002Froche-nurix-therapeutics-blood-cancer-drug-deal-060826",{"id":275,"title":276,"source":277,"logo":36,"time":140},1029105,"Roche Bets Big on Next-Gen Oncology: $2.3 Billion Collaboration with Nurix Therapeutics to Reshape Blood Cancer Treatment","https:\u002F\u002Fusaherald.com\u002Froche-bets-big-on-next-gen-oncology-2-3-billion-collaboration-with-nurix-therapeutics-to-reshape-blood-cancer-treatment",{"id":279,"title":280,"source":281,"logo":53,"time":140},1029108,"Roche–Nurix $2.3 Billion Deal for BTK Degrader Bexobrutideg in Blood Cancers","https:\u002F\u002Foncodaily.com\u002Ftechology\u002Fnurix517500",{"id":283,"title":284,"source":285,"logo":54,"time":140},1029107,"Roche Strikes $2.3B Nurix Deal for BTK Degrader","https:\u002F\u002Fwww.contractpharma.com\u002Fbreaking-news\u002Froche-strikes-2-3b-nurix-deal-for-btk-degrader",{"id":287,"title":288,"source":289,"logo":22,"time":87},1025261,"Roche bets on BTK degradation in $2.3bn Nurix deal","https:\u002F\u002Feuropean-biotechnology.com\u002Flatest-news\u002Froche-bets-on-btk-degradation-in-2-3bn-nurix-deal",{"id":291,"title":292,"source":293,"logo":5,"time":140},1029102,"Nurix Therapeutics price target raised to $34 from $26 at Needham","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fthe-fly\u002Fnurix-therapeutics-price-target-raised-to-34-from-26-at-needham-thefly-news",{"id":295,"title":296,"source":297,"logo":42,"time":87},1025260,"Nurix Therapeutics and Roche Announce Strategic Collaboration to Develop Bexobrutideg for B-Cell Malignancies and Beyond","https:\u002F\u002Fwww.quiverquant.com\u002Fnews\u002FNurix+Therapeutics+and+Roche+Announce+Strategic+Collaboration+to+Develop+Bexobrutideg+for+B-Cell+Malignancies+and+Beyond",{"id":299,"title":300,"source":301,"logo":37,"time":140},1029101,"Nurix Therapeutics Stock Pops on Roche Partnership","https:\u002F\u002Fwww.schaeffersresearch.com\u002Fcontent\u002Fnews\u002F2026\u002F06\u002F08\u002Fnurix-therapeutics-stock-pops-on-roche-partnership",{"id":303,"title":304,"source":305,"logo":5,"time":140},1029104,"Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market","https:\u002F\u002Fwww.benzinga.com\u002Fnews\u002Fhealth-care\u002F26\u002F06\u002F53056750\u002Fnurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market",{"id":307,"title":308,"source":309,"logo":5,"time":140},1029103,"Nurix Therapeutics (NRIX) Stock Drops as Roche Announces $2.3 Billion Cancer Drug Partnership","https:\u002F\u002Fblockonomi.com\u002Fnurix-therapeutics-nrix-stock-drops-as-roche-announces-2-3-billion-cancer-drug-partnership",{"id":311,"title":312,"source":313,"logo":29,"time":87},1025265,"Roche And Nurix Therapeutics: Up To $2.3 Billion Collaboration For BTK Degrader Bexobrutideg","https:\u002F\u002Fpulse2.com\u002Froche-and-nurix-therapeutics-up-to-2-3-billion-collaboration-for-btk-degrader-bexobrutideg",{"id":315,"title":316,"source":317,"logo":45,"time":87},1025264,"Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics","https:\u002F\u002Fwww.pharmaceutical-technology.com\u002Fnews\u002Froche-signs-2-3bn-blood-cancer-drug-agreement-with-nurix-therapeutics",{"id":319,"title":214,"source":320,"logo":5,"time":87},1025263,"https:\u002F\u002Fsg.finance.yahoo.com\u002Fnews\u002Froche-announces-global-collaboration-nurix-050000732.html",{"id":322,"title":323,"source":324,"logo":21,"time":140},1029100,"Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies","https:\u002F\u002Ftradersunion.com\u002Fnews\u002Fcompanies\u002Fshow\u002F2288301-nurix-roche-biotech-partnership",{"id":326,"title":327,"source":328,"logo":11,"time":87},1025262,"Roche strikes deal with Nurix Therapeutics to co-develop bexobrutideg","https:\u002F\u002Fwww.thepharmaletter.com\u002Fbiotech-news\u002Froche-strikes-deal-with-nurix-therapeutics-to-co-develop-bexobrutideg",{"id":330,"title":244,"source":331,"logo":5,"time":87},1025279,"https:\u002F\u002Ffinance.yahoo.com\u002Fmarkets\u002Fstocks\u002Farticles\u002Fnrix-stock-surges-nearly-70-101242338.html",{"id":333,"title":131,"source":334,"logo":52,"time":87},1025278,"https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Froche-enters-2-3-billion-blood-cancer-drug-deal-with-nurix-therapeutics-ce7f5dd2df8af623",{"id":336,"title":94,"source":337,"logo":48,"time":87},1025277,"https:\u002F\u002F1027wbow.com\u002F2026\u002F06\u002F08\u002Froche-enters-2-billion-cancer-drug-agreement-with-nurix-therapeutics",{"id":339,"title":340,"source":341,"logo":5,"time":140},1029117,"Roche to pay Nurix as much as US$2.3 bil in cancer drug deal","https:\u002F\u002Fsg.finance.yahoo.com\u002Fnews\u002Froche-pay-nurix-much-us-003300383.html",{"id":343,"title":344,"source":345,"logo":5,"time":140},1029116,"Roche and Nurix strike $2.3 billion blood cancer drug deal","https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Froche-nurix-strike-2-3-131705884.html",{"id":347,"title":316,"source":348,"logo":5,"time":140},1029119,"https:\u002F\u002Ffinance.yahoo.com\u002Fsectors\u002Fhealthcare\u002Farticles\u002Froche-signs-2-3bn-blood-120018454.html",{"id":350,"title":351,"source":352,"logo":5,"time":140},1029118,"Jefferies raises Nurix stock price target on Roche partnership By Investing.com","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Fjefferies-raises-nurix-stock-price-target-on-roche-partnership-93CH-4680379",{"id":354,"title":355,"source":356,"logo":12,"time":87},1025272,"Nurix Therapeutics Shares Surge Premarket on Roche Deal","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Fnurix-therapeutics-shares-surge-premarket-on-roche-deal-ce7f5dd2d18aff22",{"id":358,"title":359,"source":360,"logo":35,"time":140},1029113,"Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics","https:\u002F\u002Fwww.marketscreener.com\u002Fnews\u002Froche-enters-cancer-drug-deal-worth-up-to-2-3-billion-with-nurix-therapeutics-ce7f5dd3d980f422",{"id":362,"title":363,"source":364,"logo":10,"time":87},1025271,"Nurix (NRIX.US) surges in pre-market trading after Roche announces $2.3 billion deal to acquire rights to blood cancer drug bexobrutinib","https:\u002F\u002Fwww.moomoo.com\u002Fnews\u002Fpost\u002F71190583\u002Fnurix-nrixus-surges-in-pre-market-trading-after-roche-announces",{"id":366,"title":367,"source":368,"logo":55,"time":140},1029112,"Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying","https:\u002F\u002Fwww.investors.com\u002Fnews\u002Ftechnology\u002Fnurix-therapeutics-stock-roche-btk-degrader",{"id":370,"title":371,"source":372,"logo":32,"time":87},1025270,"Nurix surges 43% on up to $3B cancer drug deal with Roche (RHHBY:OTCMKTS)","https:\u002F\u002Fseekingalpha.com\u002Fnews\u002F4601297-nurix-surges-43-on-up-to-3b-cancer-drug-deal-with-roche",{"id":374,"title":156,"source":375,"logo":5,"time":140},1029115,"https:\u002F\u002Fwww.pharmalive.com\u002Froche-makes-up-to-3b-blood-cancer-play-with-nurixs-protein-degrader",{"id":377,"title":378,"source":379,"logo":44,"time":140},1029114,"Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg","https:\u002F\u002Fwww.pharmexec.com\u002Fview\u002Froche-2-billion-global-collaboration-nurix-therapeutics-co-develop-co-commercialize-bexobrutideg",{"id":381,"title":382,"source":383,"logo":5,"time":87},1025276,"Roche enters $2.3 billion deal with Nurix for cancer drug","https:\u002F\u002Fwww.investing.com\u002Fnews\u002Fstock-market-news\u002Froche-enters-23-billion-deal-with-nurix-for-cancer-drug-93CH-4729906",{"id":385,"title":386,"source":387,"logo":14,"time":87},1025275,"Nurix and Roche forge global BTK degrader alliance","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fcompany-announcements\u002Fnurix-and-roche-forge-global-btk-degrader-alliance",{"id":389,"title":390,"source":391,"logo":5,"time":87},1025274,"Cancer fight: Roche agrees $700M upfront for BTK degrader bexobrutideg","https:\u002F\u002Fwww.stocktitan.net\u002Fnews\u002FRHHBY\u002Froche-announces-global-collaboration-with-nurix-therapeutics-to-co-bbe9vwdvjmj5.html",{"id":393,"title":394,"source":395,"logo":5,"time":140},1029111,"Nurix stock gets Outperform rating reiterated by RBC Capital","https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Fnurix-stock-gets-outperform-rating-reiterated-by-rbc-capital-93CH-4680144",{"id":397,"title":398,"source":399,"logo":5,"time":87},1025273,"Nurix (NASDAQ: NRIX) lands $700M Roche bexobrutideg pact with up to $2.3B","https:\u002F\u002Fwww.stocktitan.net\u002Fsec-filings\u002FNRIX\u002F8-k-nurix-therapeutics-inc-reports-material-event-dca947a11cfa.html",{"id":401,"title":179,"source":402,"logo":5,"time":140},1029110,"https:\u002F\u002Fca.investing.com\u002Fnews\u002Fstock-market-news\u002Foppenheimer-reiterates-nurix-stock-rating-after-roche-deal-93CH-4680225","#78ca3dff","#78ca3d4d",1781015464280]